KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Debt (2018 - 2025)

Esperion Therapeutics' Total Debt history spans 3 years, with the latest figure at $152.2 million for Q4 2025.

  • For Q4 2025, Total Debt rose 7.98% year-over-year to $152.2 million; the TTM value through Dec 2025 reached $152.2 million, up 7.98%, while the annual FY2025 figure was $152.2 million, 7.98% up from the prior year.
  • Total Debt reached $152.2 million in Q4 2025 per ESPR's latest filing, roughly flat from $151.7 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $152.2 million in Q4 2025 to a low of $141.0 million in Q4 2024.